+

WO2008109364A3 - Nucleic acid compounds for inhibiting frap1 gene expression and uses thereof - Google Patents

Nucleic acid compounds for inhibiting frap1 gene expression and uses thereof Download PDF

Info

Publication number
WO2008109364A3
WO2008109364A3 PCT/US2008/055365 US2008055365W WO2008109364A3 WO 2008109364 A3 WO2008109364 A3 WO 2008109364A3 US 2008055365 W US2008055365 W US 2008055365W WO 2008109364 A3 WO2008109364 A3 WO 2008109364A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
gene expression
inhibiting
acid compounds
mdrna
Prior art date
Application number
PCT/US2008/055365
Other languages
French (fr)
Other versions
WO2008109364A2 (en
WO2008109364A4 (en
Inventor
Steven C Quay
James Mcswiggen
Narendra K Vaish
Mohammad Ahmadian
Original Assignee
Mdrna Inc
Steven C Quay
James Mcswiggen
Narendra K Vaish
Mohammad Ahmadian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mdrna Inc, Steven C Quay, James Mcswiggen, Narendra K Vaish, Mohammad Ahmadian filed Critical Mdrna Inc
Publication of WO2008109364A2 publication Critical patent/WO2008109364A2/en
Publication of WO2008109364A3 publication Critical patent/WO2008109364A3/en
Publication of WO2008109364A4 publication Critical patent/WO2008109364A4/en
Priority to US12/552,082 priority Critical patent/US20100105134A1/en
Priority to US13/327,545 priority patent/US20130011922A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing FRAPl gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a FRAP 1 mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a FRAPl gene in a cell or in a subject to treat a FRAP 1 -related disease.
PCT/US2008/055365 2007-03-02 2008-02-28 Nucleic acid compounds for inhibiting frap1 gene expression and uses thereof WO2008109364A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/552,082 US20100105134A1 (en) 2007-03-02 2009-09-01 Nucleic acid compounds for inhibiting gene expression and uses thereof
US13/327,545 US20130011922A1 (en) 2007-03-02 2011-12-15 Nucleic acid compounds for inhibiting gene expression and uses thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US93494007P 2007-03-02 2007-03-02
US60/934,940 2007-03-02
US93493007P 2007-03-16 2007-03-16
US60/934,930 2007-03-16
US98317907P 2007-10-27 2007-10-27
US60/983,179 2007-10-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055340 Continuation-In-Part WO2008109353A1 (en) 2007-03-02 2008-02-28 Nucleic acid compounds for inhibiting map2k gene expression and uses thereof

Related Child Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2008/055339 Continuation-In-Part WO2008109352A2 (en) 2007-03-02 2008-02-28 Nucleic acid compounds for inhibiting akt gene expression and uses thereof
AU2009212920A Division AU2009212920A1 (en) 2007-03-02 2009-09-01 Nucleic acid compounds for inhibiting gene expression and uses thereof
US12/552,082 Continuation-In-Part US20100105134A1 (en) 2007-03-02 2009-09-01 Nucleic acid compounds for inhibiting gene expression and uses thereof

Publications (3)

Publication Number Publication Date
WO2008109364A2 WO2008109364A2 (en) 2008-09-12
WO2008109364A3 true WO2008109364A3 (en) 2008-11-06
WO2008109364A4 WO2008109364A4 (en) 2008-12-31

Family

ID=39689041

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055365 WO2008109364A2 (en) 2007-03-02 2008-02-28 Nucleic acid compounds for inhibiting frap1 gene expression and uses thereof

Country Status (1)

Country Link
WO (1) WO2008109364A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9074205B2 (en) 2006-10-18 2015-07-07 Marina Biotech, Inc. Nicked or gapped nucleic acid molecules and uses thereof
WO2009143371A2 (en) * 2008-05-21 2009-11-26 Intradigm Corporation COMPOSITIONS COMPRISING mTOR SIRNA AND METHODS OF USE THEREOF

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056153A2 (en) * 2005-11-04 2007-05-18 Nastech Pharmaceutical Company Inc. Peptide-dicer substrate rna conjugates as delivery vehicles for sirna
WO2007107162A2 (en) * 2006-03-23 2007-09-27 Santaris Pharma A/S Small internally segmented interfering rna
WO2008049078A1 (en) * 2006-10-18 2008-04-24 Nastech Pharmaceutical Company Inc. Nicked or gapped nucleic acid molecules and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056153A2 (en) * 2005-11-04 2007-05-18 Nastech Pharmaceutical Company Inc. Peptide-dicer substrate rna conjugates as delivery vehicles for sirna
WO2007107162A2 (en) * 2006-03-23 2007-09-27 Santaris Pharma A/S Small internally segmented interfering rna
WO2008049078A1 (en) * 2006-10-18 2008-04-24 Nastech Pharmaceutical Company Inc. Nicked or gapped nucleic acid molecules and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRAMSEN J B ET AL: "Improved silencing properties using small internally segmented interfering RNAs", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 35, no. 17, 28 July 2007 (2007-07-28), pages 5886 - 5897, XP002467844, ISSN: 0305-1048 *
INAMURA NAOKO ET AL: "Enhancement of translation elongation in neurons by brain-derived neurotrophic factor: Implications for mammalian target of rapamycin signaling", JOURNAL OF NEUROCHEMISTRY, vol. 95, no. 5, December 2005 (2005-12-01), pages 1438 - 1445, XP002493112, ISSN: 0022-3042 *
JAWORSKI JACEK ET AL: "Control of dendritic arborization by the phosphoinositide-3'-kinase-A kt-mammalian target of rapamycin pathway", JOURNAL OF NEUROSCIENCE, vol. 25, no. 49, December 2005 (2005-12-01), pages 11300 - 11312, XP002493111, ISSN: 0270-6474 *
KIM D H ET AL: "mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 110, no. 2, 26 July 2002 (2002-07-26), pages 163 - 175, XP002966316, ISSN: 0092-8674 *
LEUSCHNER PHILIPP J F ET AL: "Cleavage of the siRNA passenger strand during RISC assembly in human cells", EMBO REPORTS, NATURE PUBLISHING GROUP, LONDON, GB, vol. 7, no. 3, 1 March 2006 (2006-03-01), pages 314 - 320, XP002443952, ISSN: 1469-221X *
MILLS JANINE B ET AL: "Origin of the intrinsic rigidity of DNA", NUCLEIC ACIDS RESEARCH,, vol. 32, no. 13, 1 January 2004 (2004-01-01), pages 4055 - 4059, XP002484664 *

Also Published As

Publication number Publication date
WO2008109364A2 (en) 2008-09-12
WO2008109364A4 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
WO2008109465A3 (en) Nucleic acid compounds for inhibiting fgfr gene expression and uses thereof
WO2008109381A3 (en) Nucleic acid compounds for inhibiting hif1a gene expression and uses thereof
WO2009029293A3 (en) Nucleic acid compounds for inhibiting myc gene expression and uses thereof
EP2322617A3 (en) Short interfering ribonucleic acid (siRNA) for oral administration
WO2010017319A3 (en) Nucleic acid compounds for inhibiting plk1 gene expression and uses thereof
WO2008109516A3 (en) Nucleic acid compounds for inhibiting ras gene expression and uses thereof
WO2010006973A3 (en) Compositions and methods for inhibiting expression of tgf-beta receptor genes
WO2008109352A3 (en) Nucleic acid compounds for inhibiting akt gene expression and uses thereof
WO2008109546A3 (en) Nucleic acid compounds for inhibiting tgfbr gene expression and uses thereof
WO2008109375A3 (en) Nucleic acid compounds for inhibiting pik3c gene expression and uses thereof
WO2010017311A3 (en) Nucleic acid compounds for inhibiting birc5 gene expression and uses thereof
WO2007137220A3 (en) Compositions and methods for inhibiting expression of ikk-b gene
WO2008109372A3 (en) Nucleic acid compounds for inhibiting pdgf gene expression and uses thereof
WO2008109350A3 (en) Nucleic acid compounds for inhibiting il6 gene expression and uses thereof
WO2008109366A3 (en) Nucleic acid compounds for inhibiting ccnd1 gene expression and uses thereof
WO2008109548A3 (en) Nucleic acid compounds for inhibiting tgfb gene expression and uses thereof
WO2008109487A3 (en) Nucleic acid compounds for inhibiting mme gene expression and uses thereof
WO2008109506A8 (en) Nucleic acid compounds for inhibiting jun gene expression and uses thereof
WO2008109495A3 (en) Nucleic acid compounds for inhibiting cd40 gene expression and uses thereof
WO2008109532A3 (en) Nucleic acid compounds for inhibiting fas gene expression and uses thereof
WO2008109443A3 (en) Nucleic acid compounds for inhibiting cdk2 gene expression and uses thereof
WO2008109558A3 (en) Nucleic acid compounds for inhibiting tlr gene expression and uses thereof
WO2008109364A3 (en) Nucleic acid compounds for inhibiting frap1 gene expression and uses thereof
WO2011139842A3 (en) Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
WO2008109493A3 (en) Nucleic acid compounds for inhibiting cd19 gene expression and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08731019

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08731019

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载